FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
Enanta Pharma (NASDAQ: ENTA) Falls 25% Despite "Positive" Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
Study Met Primary Endpoints of Safety and TolerabilityDose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to... More
